Solid biosciences announces closing of acquisition of aavantibio and concurrent $75 million private placement

- transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran bo cumbo -

SLDB Ratings Summary

SLDB Quant Ranking